Key facts
- This page summarizes Christopher Ray Aker's Form 4 filing for Regulus Therapeutics Inc. (RGLS).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 18 Jan 2024, 20:23.
Christopher Ray Aker - 18 Jan 2024 Form 4 Insider Report for Regulus Therapeutics Inc. (RGLS)
- Reporting relationship
- Sr. VP & General Counsel
- Issuer ticker
- RGLS
- Reported as of
- 18 Jan 2024
- Net transaction value
- -$6,510
- SEC form
- 4
- Accepted by SEC
- 18 Jan 2024, 20:23:30 UTC
- Prior SEC filing
- 17 Jan 2024
- Next SEC filing
- 21 May 2024
- Source filing
- View source filing
- Reporting owner signature
- Christopher Aker
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Christopher Ray Aker filed Form 4 for Regulus Therapeutics Inc. (RGLS) on 18 Jan 2024.
Change
- Previous filing in this sequence was filed on 17 Jan 2024.
- Current net transaction value: -$6,510.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
RGLS
transaction
Common Stock
Sale
- Transaction value
- $6,510
- Shares
- -5,468
- Change %
- -35%
- Price
- $1.19
- Shares after
- 10,056
- Date
- 18 Jan 2024
- Ownership
- Direct
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
The sales reported on this Form 4 represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs) received by the Reporting Person. These sales are made pursuant to an existing 10b5-1 plan under which the Reporting Person has irrevocably elected to satisfy the tax obligations through this sale and do not represent discretionary trades by the Reporting Person.